Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS by Stephane Legriel et al.
Legriel et al. Ann. Intensive Care  (2016) 6:54 
DOI 10.1186/s13613-016-0159-z
REVIEW
Neuroprotective effect of therapeutic 
hypothermia versus standard care alone 
after convulsive status epilepticus: protocol 
of the multicentre randomised controlled trial 
HYBERNATUS
Stephane Legriel1,2*, Fernando Pico3, Yves‑Roger Tran‑Dinh4, Virginie Lemiale5, Jean‑Pierre Bedos1, 
Matthieu Resche‑Rigon6,7,8 and Alain Cariou2,9,10
Abstract 
Convulsive status epilepticus (CSE) is a major medical emergency associated with a 50 % morbidity rate. CSE guide‑
lines have recommended prompt management for many years, but there is no evidence to date that they have sig‑
nificantly improved practices or outcomes. Developing neuroprotective strategies for use after CSE holds promise for 
diminishing morbidity and mortality rates. Hypothermia has been shown to afford neuroprotection in various health 
conditions. We therefore designed a trial to determine whether 90‑day outcomes in mechanically ventilated patients 
with CSE requiring management in the intensive care unit (ICU) are improved by early therapeutic hypothermia 
(32–34 °C) for 24 h with propofol sedation. We are conducting a multicentre, open‑label, parallel‑group, randomised, 
controlled trial (HYBERNATUS) of potential neuroprotective effects of therapeutic hypothermia and routine propofol 
sedation started within 8 h after CSE onset in ICU patients requiring mechanical ventilation. Included patients are 
allocated to receive therapeutic hypothermia (32–34 °C) plus standard care or standard care alone. We plan to enrol 
270 patients in 11 ICUs. An interim analysis is scheduled after the inclusion of 135 patients. The main study objective 
is to evaluate the effectiveness of therapeutic hypothermia (32–34 °C) for 24 h in diminishing 90‑day morbidity and 
mortality (defined as a Glasgow Outcome Scale score <5). The HYBERNATUS trial is expected to a decreased propor‑
tion of patients with a Glasgow Outcome Scale score lower than 5 after CSE requiring ICU admission and mechanical 
ventilation.
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Background
Convulsive status epilepticus (CSE) is a life-threatening 
emergency that requires on-scene antiepileptic treat-
ment adjusted according to the treatment response [1]. 
Hospital mortality is about 20 % overall and reaches 40 % 
in patients with severe refractory CSE [2]. The morbidity 
associated with CSE is more difficult to evaluate, as 
adverse events are often erroneously attributed to the 
cause of CSE. In retrospective studies, Glasgow Outcome 
Scale (GOS) scores indicated neurological impairments 
in 28  % of patients after CSE and 54  % after refractory 
CSE [3]. In a prospective multicentre study, 50 % of CSE 
survivors requiring ICU admission had impaired 90-day 
functional outcomes defined as a GOS score <5 [4]. By 
multivariate analysis, factors independently associ-
ated with poorer outcomes were age, duration of motor 
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seizures, focal neurological signs, and progression to 
refractory status epilepticus (SE) [4]. Some of these fac-
tors may be amenable to improvement and therefore may 
constitute therapeutic targets. Thus, outcomes may be 
improved by the rapid control of seizure activity (shorter 
seizure duration and prevention of refractory CSE and 
NCSE) and by treatment of the cause of CSE [5, 6].
Therapeutic hypothermia has shown both anticon-
vulsant and neuroprotective properties after SE in 
experimental studies. In rats, hypothermia at 32–34  °C 
decreased the incidence of both seizures and associ-
ated local and hippocampal neuronal damage [7–13]. In 
humans, therapeutic hypothermia has been described 
merely as an adjuvant treatment of super-refractory SE in 
adults and paediatric patients [14–17]. Finally, therapeu-
tic hypothermia may also target some of the causes of sta-
tus epilepticus such as ischaemic or haemorrhagic stroke 
[18–22] and subarachnoid haemorrhage [23–25]. Its use 
in patients with traumatic brain injury demonstrated 
conflicting results [26–30]. Thus, pathophysiological con-
siderations and experimental data suggest a beneficial 
effect of therapeutic hypothermia in SE. Proof of such an 
effect in human patients has not been obtained [31, 32].
The main goal of the HYBERNATUS trial is to deter-
mine whether therapeutic hypothermia (32–34  °C) for 
24  h has neuroprotective effects compared to standard 
care alone. HYBERNATUS is a multicentre, open-label, 
parallel-group, randomised, controlled trial in patients 
with CSE requiring admission to the intensive care unit 
(ICU) and mechanical ventilation.
Methods/design
Ethical aspects
The study protocol was approved by the local inde-
pendent ethics committee (Comité de Protection des 
Personnes CPP Ile de France IV, Saint Louis, on 1 Sep-
tember 2010, #2010/27) and the competent French 
health authorities (AFSSAPS, on 22 June 2010, #EudraCT 
2010-A00466-33). Informed consent is obtained from 
each patient or next of kin prior to study inclusion. 
The trial was registered at Clinicaltrials.gov identifier 
NCT01359332 (registered on 23 May 2011).
Aims
The main study objective is to evaluate the effective-
ness of therapeutic hypothermia (32–34  °C) for 24  h in 
decreasing 90-day morbidity and mortality, defined as a 
GOS score <5, in patients with CSE requiring ICU admis-
sion and mechanical ventilation.
The secondary objectives are to evaluate the effective-
ness of therapeutic hypothermia (32–34  °C) for 24  h in 
decreasing seizure duration, progression to refractory 
CSE, ICU mortality, hospital mortality, 90-day mortality, 
hospital stay length, and 90-day functional impairments 
(motor and/or cognitive impairment, epilepsy).
Design
HYBERNATUS is a multicentre, open-label, parallel-
group, randomised, controlled trial in patients with CSE 
requiring ICU admission and mechanical ventilation. 
Patients are allocated at random to either early thera-
peutic hypothermia plus standard care or standard care 
alone at the acute phase of ICU management.
Setting
Among the 11 French ICUs participating in the study, 
6 are in university hospitals. All participating ICU staff 
members have received training in the study procedures 
and in protocols for optimal CSE management.
Study population
Inclusion criteria are age over 18 years, admission to one 
of 11 participating ICUs, CSE (5 min or more of contin-
uous clinical seizure activity or more than two seizures 
without a return to baseline in the interval), time since 
seizure onset no longer than 8 h, and need for mechani-
cal ventilation.
Exclusion criteria are a full recovery, need for emer-
gent surgery (neurosurgery or other) precluding thera-
peutic hypothermia, postanoxic status epilepticus, dying 
patient, decision to withdraw or withhold life-sustaining 
treatments, and pregnancy.
All patients admitted to one of the participating ICUs 
with any seizure activity are screened for eligibility by the 
ICU physicians 24/7.
Randomisation
Consecutive eligible patients are randomly allocated in 
a 1:1 ratio to one of the two treatment groups. The ran-
domisation scheme involves permuted blocks and strati-
fication on centre, age (≤65 or >65  years), and seizure 
duration (≤60 min or >60 min). Randomisation and con-
cealment are ensured by using a secure, computer-gener-
ated, interactive, response system available at each study 
centre and managed by the biometrics unit of the Saint 
Louis University Hospital (Paris, France), which has no 
role in patient recruitment.
Study interventions
The study protocol and randomisation arms are detailed 
in Figs. 1 and 2 and Table 1.
Standardised anticonvulsant treatments 
after randomisation in both groups
To be eligible, patients should have received at least one 
of the first-line anticonvulsant drugs (clonazepam and 
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diazepam) listed in French guidelines. Patients with 
ongoing motor seizures who have not received a second-
line anticonvulsant (fosphenytoin, phenytoin, phenobar-
bital, or sodium valproate) before randomisation receive 
a loading dose of one of these drugs selected according 
to the indications and specific contraindications of each 
[33].
Patients with refractory CSE, defined as CSE persist-
ing despite two lines of anticonvulsant therapy within 
60 min, are given an intravenous 2 mg/kg propofol bolus 
followed by an additional intravenous 1  mg/kg bolus 
every 5  min until motor seizures stop, at which point 
a continuous intravenous propofol infusion is started 
at a rate of 2–5  mg/kg/h. In patients with uncontrolled 
refractory CSE despite continuous intravenous propofol 
at a rate of 5 mg/kg/h, anaesthetic drugs (midazolam or 
thiopental) can be added.
CSE must be controlled within 60 min after randomisa-
tion in both groups and before the induction of therapeu-
tic hypothermia in the experimental group.
Therapeutic hypothermia group
The objective is to lower the core body temperature 
to 32–34  °C rapidly after randomisation and then to 
maintain this temperature for 24  h. The management 
in the therapeutic hypothermia group will include the 
following:
  • sedation with propofol in a 1–2 mg/kg bolus followed 
by a maintenance infusion at a rate of 2–5 mg/kg/h; 
patients with refractory CSE before randomisation 
receive the propofol infusion rate that was required 
to stop the motor seizures;
  • neuromuscular blockade with a 0.15 mg/kg bolus of 
cisatracurium or of another neuromuscular blocker 
followed by doses at 4-h intervals adjusted to main-
tain the response to train-of-four stimulation at two 
of four twitches;
  • hypothermia induction with ice-cold intravenous flu-
ids at 4  °C and then hypothermia maintenance with 
ice packs at the groin and neck and a cold-air tunnel 
around the patient’s body;
  • after 24  h of hypothermia, passive rewarming by 
covering the patient with a warm blanket, at a slow 
rate of 0.25–0.5  °C per hour to avoid haemody-
namic instability, cisatracurium is discontinued when 
normothermia is achieved; when the train-of-four 
response is four twitches, the propofol is stopped or 
Fig. 1 HYBERNATUS trial diagram. ICU intensive care unit. EEG electroencephalogram
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decreased to the lowest dose needed to ensure toler-
ance of the endotracheal tube;
  • If continued sedation is required, the choice of the 
sedative is at the discretion of the bedside physician, 
but propofol is not used for longer than 48 h;
  • Core body temperature is monitored using an 
oesophageal probe throughout the therapeutic hypo-
thermia phase and then during rewarming until two 
values 4 h apart are between 37° and 38° C.
Control group
The bedside physician decides whether sedation should 
be initiated and maintained. If sedation is given, the 
same propofol regimen as in the therapeutic hypother-
mia group is used (1–2  mg/kg bolus and then 2–5  mg/
kg/h intravenous infusion rate). If sedation is inad-
equate with continuous intravenous propofol 5  mg/
kg/h, benzodiazepines may be added. Finally, if sedation 
must be maintained beyond 48 h, the propofol must be 
stopped and an anaesthetic selected by the bedside physi-
cian given instead.
General management of convulsive status epilepticus 
(CSE) in both groups
In both control and intervention groups, a continuous 
EEG monitoring is started within 2  h after randomisa-
tion and maintained during the first 48 h after randomi-
sation and/or until body temperature normalisation in 
the therapeutic hypothermia group. A 30-min standard 
EEG extracted from the continuous EEG recording is 
sent for centralised interpretation by a qualified neu-
rophysiologist within 2 h after the initiation of continu-
ous EEG monitoring. If the results show refractory CSE 
or progression to NCSE, the patient is given a 2-mg/kg 
Fig. 2 Eligibility criteria, inclusion, randomisation, and treatment implementation modalities in each arm of the trial
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propofol bolus, repeated every 5  min if necessary, and 
then a maintenance intravenous infusion at 2–5 mg/kg/h 
to obtain and maintain a burst-suppression EEG pattern 
for 24  h. Further EEG epochs are sent for centralised 
interpretation by a qualified neurophysiologist until a 
burst-suppression EEG pattern is observed.
Second-line anticonvulsant drugs administered intra-
venously are switched to enteral administration when 
feasible. Patients with a known history of epilepsy are 
given their previous treatment enterally or parenter-
ally. Aetiological investigations are carried out early, 
simultaneously with the symptomatic and anticonvul-
sant treatment. They include a thorough initial physical 
examination and tests for metabolic disturbances (e.g. 
hypoglycaemia, hypocalcaemia, hyponatraemia, urae-
mia, hypomagnesaemia, hypoxaemia, and hypercapnia) 
and carbon monoxide poisoning. Computed tomogra-
phy (CT) of the brain is performed routinely. In patients 
with previously treated epilepsy, serum anticonvulsant 
drug assays are performed if appropriate, to determine 
whether levels are within the therapeutic range. As dic-
tated by the clinical setting, tests are performed for dis-
orders such as porphyria and thyroid dysfunction and/or 
for toxic substances (alcohol, cocaine, amphetamines, tri-
cyclic, or serotonergic antidepressants). A lumbar punc-
ture is performed in patients with any of the following: 
fever, meningeal neck stiffness, immunodeficiency, and 
negative findings from the other aetiological investiga-
tions. Magnetic resonance imaging (MRI) may be con-
sidered if all other aetiological investigations are negative 
[34].
Other general measures
In both groups, a standardised neurological examination 
is performed every 4  h by the physicians and nurses in 
charge of the patient (GOS score, pupillary reflex, corneal 
reflex, cough reflex, spontaneous breathing, abnormal 
movements, focal neurological signs). Core body tem-
perature is monitored continuously using an oesophageal 
probe and recorded every 4 h during the first 48 h after 
randomisation.
Patients are routinely screened for propofol infusion 
syndrome via measurements of arterial blood gas, serum 
lactate, serum triglycerides, and serum creatine phospho-
kinase every 8 h during the first 48 h after randomisation.
The prevention of secondary brain injury relies on tem-
perature control to avoid hyperthermia in the control 
group and, after rewarming, in the therapeutic hypo-
thermia group; glucose control between 0.8 and 1.4 g/L, 
maintenance of normoxia with PaO2  ≥  80  mmHg and 
SaO2 ≥  95  %; maintenance of normocapnia with PCO2 
between 35 and 40  mmHg; 45° head-of-bed eleva-
tion; maintenance of mean arterial pressure between 
70 and 90  mmHg; and serum sodium control between 
Table 1 HYBERNATUS trial flow chart
1 By phone interview in all cases
2 Neurologist visit, if feasible










Eligibility: check inclusion and non‑inclusion criteria X
Patient/next of kin information and consent X
Randomisation (within 8 h after CSE onset) X
Standardised anticonvulsant treatment X
Brain imaging and other aetiological investigations X
Therapeutic hypothermia (in the intervention group) X X
Core temperature monitoring (every 4 h) X X
Continuous EEG monitoring X X
30‑min continuous EEG extract (centralised reading) X X
Clinical and laboratory monitoring X X X X
Serious adverse event reporting X X X X X X




FIM scale score X2
Neurological evaluation X2
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138 and 142  mmol/L. Special attention is paid to the 
occurrence of aspiration pneumonia, and three samples 
for blood cultures are taken routinely within 24  h after 
randomisation.
Safety and potential risks associated with the study
Rigorous monitoring procedures are implemented to 
minimise the risks associated with therapeutic hypother-
mia in patients after CSE. Continuous EEG monitoring 
is performed for 48 h after inclusion, and a 30-min EEG 
extract is interpreted centrally before implementation of 
the randomly allocated treatments. Although neuromus-
cular blockade can theoretically mask recurrent seizure 
activity, this risk is lessened by the anticonvulsant prop-
erties of therapeutic hypothermia.
Preliminary data show that 82 % of patients admitted to 
the ICU for CSE receive mechanical ventilation for longer 
than 24 h, and that nearly 25 % of those given mechani-
cal ventilation for less than 24 h have a 90-day GOS score 
lower than 5. Thus, the use of mechanical ventilation for 
an unnecessarily long period seems very rare. No crite-
ria are available for predicting which patients will require 
mechanical ventilation for less than 24  h. Finally, this 
study includes only patients with severe CSE requiring 
both ICU admission and mechanical ventilation.
Patients receiving therapeutic hypothermia and/or 
propofol are closely monitored for adverse effects of 
these treatments such as infections and propofol infusion 
syndrome. We therefore believe that the use of therapeu-
tic hypothermia does not expose the patients to undue 
risks, given the high morbidity and mortality rate in our 
prospective study [4] and the safety measures included in 
the HYBERNATUS trial protocol.
Data collection and follow‑up
The following baseline characteristics are recorded at 
admission: age, sex, date and time of ICU admission, 
McCabe score and Knaus score, and pre-existing comor-
bidities. The Simplified Acute Physiology Score II is com-
puted 24 h after ICU admission.
The study protocol also requires collection of the fol-
lowing data:
  • Description of the CSE: circumstances of onset, date 
and time of onset and of seizure control, clinical fea-
tures of seizures, pre-hospital and hospital providers 
and timing of anticonvulsant and supportive treat-
ments, results of aetiological investigations (brain 
CT, lumbar puncture, MRI, laboratory tests including 
toxicological screen), aetiological diagnosis, type and 
dosage of antiepileptic drugs, and date and start and 
stop times of continuous EEG monitoring;
  • Data related to ICU and hospital management: 
description of the acute disease; description of 
organ failures according to the Logistic Organ Dys-
function score (at inclusion and on days 0, 1, 2, 7, 
14, and 28); use of mechanical ventilation, inotropic 
support, and/or renal replacement therapy; vital 
and functional status at ICU and hospital discharge 
according to the GOS; and cause of death (treat-
ment limitation decision, refractory SE, and/or ICU 
complications);
  • Data related to therapeutic hypothermia: modali-
ties of induction and maintenance; core tempera-
ture every 4 h during the first 48 h; serum levels of 
creatine phosphokinase, triglycerides, and electro-
lytes; arterial lactate and blood gas levels; electrocar-
diogram; occurrence of aspiration pneumonia; and 
results of blood cultures on samples taken within the 
first 24 h;
  • Data related to outcomes: 90-day GOS score by 
structured phone interview and neurologist visit; 
description of functional sequelae; mini–mental state 
examination (MMSE) score; and Functional Inde-
pendence Measure scale (FIM) score.
Organisation of the trial
Funding/support
HYBERNATUS is fully sponsored by the Direction de la 
Recherche Clinique et du Développement (DRCD), Assis-
tance Publique—Hopitaux de Paris, France, with a grant 
from the French Ministry of Health (Programme Hospi-
talier de Recherche Clinique, PHRC AOM 09 180). There 
is no industry sponsorship or funding.
Coordination and conduct of the trial
Before recruitment of the first patient, all physicians and 
other healthcare workers in the 11 participating ICUs 
attended formal training sessions on the study proto-
col, data collection in the case-report form (CRF), and 
implementation of continuous EEG monitoring. All 
documents required for the study, including the study 
protocol and management guidelines, are available in 
each participating ICU. In each participating ICU, the 
physicians and a clinical research nurse and/or clinical 
research assistant are in charge of daily patient screening 
and inclusion, ensuring compliance with the study pro-
tocol, and collecting the study data in the CRF. Finally, 
all participating physicians are available for inclusion 
and continuous EEG monitoring around the clock and 
7 days per week. The DRCD clinical research unit regu-
larly reviews all clinical data collected in the CRF. Any 
serious adverse event must be reported within 48 h after 
its occurrence.
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Interim analyses
An interim analysis is scheduled after the enrolment of 
135 patients. The O’Brien-Fleming method will be used.
Blinding
Blinding of the physicians, nurses, and patients to the 
use of therapeutic hypothermia is not feasible. To mini-
mise evaluation bias, outcomes will be evaluated during 
a structured phone interview by independent assessors 
blinded to the allocation group.
Study outcomes
Primary outcome
The primary outcome is GOS score determined by a 
structured interview lower than 5 on day 90.
Secondary outcomes
Secondary outcomes are as follows:
  • Percentages of patients with recurrent convulsive 
and/or non-convulsive seizures between 6 and 12 h 
after randomisation
  • Total seizure duration in minutes
  • Percentage of patients with refractory status epilep-
ticus
  • Mortality in the ICU, in the hospital, and by day 90
  • Total ICU and hospital stay lengths in days
  • Percentages of patients with functional impairments 
on day 90: frequency of seizures, recurrence of status 
epilepticus after discharge, number of antiepileptic 
drugs, MMSE score, and FIM score
Modalities of outcome evaluation
The GOS score is determined on day 90 (±7 days) during 
a structured phone interview conducted by an independ-
ent assessor blinded to the allocation group (Table 2).
When possible, on day 90 (±7 days), patients return to 
the centre where they were included, for an evaluation 
by a neurologist including an interview and determina-
tion of the GOS score by structured interview, MMSE 
score, and FIM score. The patient brings an MRI of the 
brain and conventional EEG. The neurologist records any 
recurrent CSE episodes since randomisation; frequency 
of any recurrent seizures, as well as their type and associ-
ated symptoms; nature and dosage of antiepileptic drugs; 
and other treatments.
Independent data safety monitoring board (DSMB)
The independent data safety monitoring board (DSMB) 
is composed of three physicians (Thomas De Broucker, 
Neurology Department, Saint Denis Hospital, Saint 
Denis, France; Alain Combes, Intensive Care Unit, Pitié 
Salpétrière University Hospital, France; and Nicolas 
Pichon, Intensive Care Unit, Limoges University Hos-
pital, Limoges, France) and one biostatistician (Patricia 
Jabre, Urgences-Samu 93, Avicenne University Hospi-
tal, Bobigny, France) not otherwise involved in the trial. 
The DSMB assesses the safety data whenever complete 
90-day follow-up data become available for 45 addi-
tional patients. For each of these safety analyses, the 
DSMB has access to blinded results on 28-day mortal-
ity, ICU discharge mortality, and 90-day GOS scores. 
The DSMB also evaluates all reported serious adverse 
events.
End of the trial
Each patient is in the trial for 90 days. Premature study 
withdrawal is considered if requested by the patient or 
next of kin. Patients who are lost to follow-up or do not 
receive the randomly assigned treatment are not classi-
fied as prematurely withdrawn from the trial. Prema-
turely withdrawn patients are not replaced but undergo 
the procedures scheduled for the last visit, to the extent 
possible. Furthermore, the reason for premature with-
drawal is recorded in both the CRF and the source 
document.
Sample size
The working hypothesis for this randomised controlled 
trial is that, compared to standard care alone, standard 
care combined with therapeutic hypothermia increases 
the proportion of patients with a good 90-day out-
come defined as a GOS score of 5. Assuming that 40 % 
of patients will have a GOS score of 5 on day 90 in the 
standard care group [4] and that this percentage will 
increase by 20  % (to 60  %) with therapeutic hypother-
mia, with a 5 % two-sided type I error rate, 90 % power, 
and a single interim analysis performed according to the 
O’Brien-Fleming method, 135 patients are needed in 
each group (270 patients in all).
Statistical methods
The statistical analysis will follow the intention-to-treat 
approach, with each patient being analysed as a member 
of the group assigned by randomisation, regardless of 
subsequent events. In addition, any missing value will be 
replaced by the previous value according to the last value 
carried forward method. A sensitivity analysis of miss-
ing values will be carried out, using multiple imputation 
by chained equations (MICE). Comparisons of the two 
groups will routinely consider a possible centre effect.
A statistical analysis report will be written to describe 
all the findings according to CONSORT statement rec-
ommendations, taking into account the specific features 
of the trial. Any change in the analysis plan will be justi-
fied in the final report.
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Primary outcome
The primary outcome will be assessed by using logistic 
regression to compare the percentage of patients with a 
90-day GOS score lower than 5 in the two study groups. 
If needed, the logistic regression model will be adjusted 
to allow a more accurate assessment of the effect.
Secondary outcomes
The method described above for the primary outcome 
will also be used for the percentages of patients with 
EEG evidence of an ongoing epileptic seizure between 
6 and 12 h or of refractory SE after randomisation; ICU, 
hospital, and 90-day mortality; and 90-day functional 
impairments.
To compare seizure duration (in minutes), we will build 
a semi-parametric regression model (Cox or Fine–Gray) 
appropriate for an analysis of competing risks (control of 
SE vs. death without control of SE). This approach will be 
used also for ICU and hospital stay lengths (alive at ICU 
or hospital discharge vs. death in the ICU or hospital, 
respectively).
Discussion
SE is among the most common and challenging life-
threatening events in patients with neurological failure. 
Despite national and international guidelines empha-
sising the importance of urgent anticonvulsant therapy 
according to a stepwise algorithm, SE remains associated 
with high mortality and morbidity rates. The contrast 
between the dual anticonvulsant and neuroprotective 
properties of therapeutic hypothermia demonstrated 
in experimental studies, on the one hand, and the pau-
city of clinical evidence, on the other, combined with the 
potential beneficial effects of therapeutic hypothermia on 
several causes of SE, prompted us to design the HYBER-
NATUS trial [35].
Several key points of the trial design received special 
attention and deserve discussion. First, our focus on 
patients with CSE requiring ICU management is war-
ranted by reports of severe functional impairments after 
CSE. Indeed, the main objective of the study is neu-
roprotection, as opposed to only seizure control. We 
hypothesised that early implementation of our neuro-
protective strategy in comatose patients after the control 
of CSE would translate into improved 90-day outcomes. 
We therefore decided to include not only patients with 
refractory CSE, but also all patients remaining comatose 
after control of motor seizures. Similarly, we planned to 
include patients regardless of the underlying aetiology 
even if this may lead to heterogeneity. As we were unwill-
ing to require the use of mechanical ventilation for the 
trial, we included only patients who needed mechanical 
ventilation for any medical reason after CSE. Second, the 
choice of 32–34 °C as the therapeutic hypothermia target 
rests on both data from experimental animal models of 
SE and current practice regarding the use of therapeutic 
hypothermia in various conditions such as coma after 
cardiac arrest, stroke, or even traumatic brain injury [27, 
36, 37]. Finally, the 24-h duration of therapeutic hypo-
thermia after CSE control is based on the current stand-
ard of care for refractory SE, which includes anaesthetics 
for up to 24 h with a burst-suppression EEG pattern [5, 
32]. Third, therapeutic hypothermia requires sedation 
and neuromuscular blockade. To ensure patient awak-
ening as early as possible after the end of the neuropro-
tective procedure, we chose drugs with short half-lives, 
Table 2 Categories of the Glasgow Outcome Scale Adapted from Jennett B et al.
Category Classification Description
1 Death Patient is certified dead
2 Vegetative state Patient is unable to interact with the environment
Patients who show no evidence of meaningful responsiveness. This non‑sentient state must be distinguished from other 
conditions of wakeful, reduced responsiveness–such as the locked‑in syndrome, akinetic mutism, and total global apha-
sia. Vegetative patients breathe spontaneously, have periods of spontaneous eye‑opening, may follow moving objects 
with their eyes, show reflex responses in their limbs (to postural or painful stimuli), and they may swallow food placed in 
their mouths
3 Severe disability Patient is unable to live independently but can follow commands
This indicates that a patient is conscious but needs the assistance of another person for some activities of daily living every 
day. This may range from continuous total dependency to the need for assistance with only one activity
4 Moderate disability Patient is capable of living independently but unable to return to work or school
Such a patient is able to look after himself at home, to get out, and about to the shops and to travel by public transport. 
However, some previous activities, either at work or in social life, are now no longer possible by reason of either physical or 
mental deficit
5 Mild or no disability Patient is able to return to work or school
This indicates the capacity to resume normal occupational and social activities, although there may be minor physical or 
mental deficits. However, for various reasons, the patient may not have resumed all his previous activities and in particu-
lar may not be working
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such as propofol and cisatracurium. Propofol has the 
additional advantage of exerting anticonvulsant effects. 
However, we felt it would be unethical to require the use 
of sedation in patients in the control arm. Thus, the con-
tinuation of sedation in controls is at the discretion of the 
bedside physician. Finally, safety considerations led us 
to limit the use of propofol to 48 h with an infusion rate 
no greater than 5 mg/kg/h, in both arms [38]. Fourth, we 
chose the 90-day GOS score as the primary outcome. The 
GOS is used chiefly to evaluate overall outcomes of neu-
rological conditions [39–41]. The GOS in its structured 
form has been found valid, practical, and reliable [42]. 
It also has the advantage of having been used in several 
studies of SE, and it is well suited to an assessment of the 
physical and functional burden after CSE [43]. Moreo-
ver, in the preliminary work that allowed us to formulate 
the hypothesis for the sample size estimation, the 90-day 
functional outcome was evaluated using the GOS [4]. 
Importantly, the GOS has been found valid, practical, 
and reliable [42, 44].
To conclude, one of the main strengths of the HYBER-
NATUS trial is the uniformity of the study population 
and careful standardisation of CSE management in both 
groups. All patients are managed according to the recent 
literature, with continuous EEG monitoring and a com-
prehensive aetiological workup. The only difference 
between the two groups is the use of therapeutic hypo-
thermia at 32–34  °C for 24  h, which is determined by 
randomisation. If the study hypothesis is confirmed, ther-
apeutic hypothermia at 32–34 °C after control of CSE in 
patients requiring mechanical ventilation and ICU man-
agement will become part of standard practice in order to 
improve patient outcomes.
Study protocol amendments and safety monitoring
Following first communication of a study indicating that 
moderate hypothermia may be harmful in patients with 
severe bacterial meningitis [45], we submitted a protocol 
amendment to the local independent ethics committee 
(Comité de Protection des Personnes CPP Ile de France 
IV, Saint Louis, on 15 January 2013) to not enrol patients 
with bacterial meningitis. This change was implemented 
on 24 January 2013.
Based on the results of planned the interim analysis 
(May 2013), the DSMB recommended the continuation 
of patients recruitment.
Trial status
The trial has been validated and accepted for finan-
cial support by the French National Health Minis-
try (Programme Hospitalier de Recherche Clinique, 
PHRC AOM 09-P081249). Patient inclusion started 
in March 2011, and enrolments were completed on 
January 2015. Data management and planned analysis 
are ongoing, and release of the results is planned for 
the end of 2016.
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